SCHEMBL21943013

SCHEMBL21943013

Cc1ccc(Oc2cc(-c3cccnc3)nc3c2ccn3C)cc1C(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 5/20 0.54
▸ KDR P35968 5/20 0.54
▸ CSF1R P07333 3/20 0.54
▸ KIT P10721 3/20 0.54
▸ BRAF P15056 3/20 0.51
▸ LCK P06239 6/20 0.49
▸ SRC P12931 3/20 0.49
▸ MET P08581 3/20 0.49
▸ BTK Q06187 3/20 0.49
▸ ABL1 P00519 3/20 0.49
▸ BCR P11274 3/20 0.49
▸ LMNA P02545 3/20 0.49
▸ DDR1 Q08345 3/20 0.49
▸ DDR2 Q16832 3/20 0.49
▸ ESYT2 A0FGR8 2/20 0.49
▸ NBAS A2RRP1 2/20 0.49
▸ CNOT1 A5YKK6 2/20 0.49
▸ TBKBP1 A7MCY6 2/20 0.49
▸ AGPS O00116 2/20 0.49
▸ MYO1F O00160 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21943452 0.92 KDR (0.47) MAPK14KDRCSF1RKITBRAF
SCHEMBL21943070 0.89 MEN1 (0.53) MAPK14KDRCSF1RKITBRAF
SCHEMBL21943534 0.87 KDR (0.58) MAPK14KDRCSF1RKITBRAF
SCHEMBL21943735 0.87 BRAF (0.51) MAPK14KDRCSF1RKITBRAF
SCHEMBL21943007 0.86 PIKFYVE (0.61) MAPK14KDRCSF1RKITBRAF
SCHEMBL21943638 0.85 BRAF (0.54) MAPK14KDRCSF1RKITBRAF
SCHEMBL21943517 0.84 TEK (0.57) MAPK14KDRCSF1RKITBRAF
SCHEMBL22024636 0.81 ABL1 (0.55) MAPK14KDRCSF1RBRAFLCK
SCHEMBL21943069 0.81 KDR (0.51) KDRKITBRAFPDGFRBFGFR1
SCHEMBL22024696 0.80 ABL1 (0.67) MAPK14KDRCSF1RKITBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof XIAMEN UNIVERSITY (CN) 2022-05-03 — — US disclosed
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF XIAMEN UNIVERSITY (CN) 2020-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF CYP4A11, CYP2D6, CYP3A43 MAPK14 926/4885KDR 2067/4885CSF1R 3749/4885
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof CYP4A11, CYP2D6, CYP3A43 MAPK14 926/4885KDR 2067/4885CSF1R 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback